Localization matters: nuclear-trapped Survivin sensitizes glioblastoma cells to temozolomide by elevating cellular senescence and impairing homologous recombination
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1420-9071
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Localization matters: nuclear-trapped Survivin sensitizes glioblastoma cells to temozolomide by elevating cellular senescence and impairing homologous recombination ; volume:78 ; number:14 ; day:8 ; month:6 ; year:2021 ; pages:5587-5604 ; date:7.2021
Cellular and molecular life sciences ; 78, Heft 14 (8.6.2021), 5587-5604, 7.2021
- Urheber
-
Reich, Thomas R.
Schwarzenbach, Christian
Vilar, Juliana Brandstetter
Unger, Sven
Mühlhäusler, Fabian
Nikolova, Teodora
Poplawski, Alicia
Baymaz, H. Irem
Beli, Petra
Christmann, Markus
Tomicic, Maja T.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00018-021-03864-0
- URN
-
urn:nbn:de:101:1-2021101518543359095652
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:27 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Reich, Thomas R.
- Schwarzenbach, Christian
- Vilar, Juliana Brandstetter
- Unger, Sven
- Mühlhäusler, Fabian
- Nikolova, Teodora
- Poplawski, Alicia
- Baymaz, H. Irem
- Beli, Petra
- Christmann, Markus
- Tomicic, Maja T.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1–Survivin axis
Inhibition of gap junctions sensitizes primary glioblastoma cells for temozolomide
Survivin gene silencing sensitizes prostate cancer cells to selenium growth inhibition
GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment
Targeting TPC2 sensitizes acute lymphoblastic leukemia cells to chemotherapeutics by impairing lysosomal function
Epigenetic preconditioning with decitabine sensitizes glioblastoma to temozolomide via induction of MLH1
BET inhibitor I-BET151 sensitizes GBM cells to temozolomide via PUMA induction
Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF)
BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression
miR-494 Sensitizes Gastric Cancer Cells to TRAIL Treatment Through Downregulation of Survivin
miR-1297 sensitizes glioma cells to temozolomide (TMZ) treatment through targeting adrenomedullin (ADM)
Retraction Note: BET inhibitor I-BET151 sensitizes GBM cells to temozolomide via PUMA induction
Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1–Survivin axis
Inhibition of gap junctions sensitizes primary glioblastoma cells for temozolomide
Survivin gene silencing sensitizes prostate cancer cells to selenium growth inhibition
GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment
Targeting TPC2 sensitizes acute lymphoblastic leukemia cells to chemotherapeutics by impairing lysosomal function
Epigenetic preconditioning with decitabine sensitizes glioblastoma to temozolomide via induction of MLH1
BET inhibitor I-BET151 sensitizes GBM cells to temozolomide via PUMA induction
Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF)
BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression
miR-494 Sensitizes Gastric Cancer Cells to TRAIL Treatment Through Downregulation of Survivin
miR-1297 sensitizes glioma cells to temozolomide (TMZ) treatment through targeting adrenomedullin (ADM)
Retraction Note: BET inhibitor I-BET151 sensitizes GBM cells to temozolomide via PUMA induction
Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1–Survivin axis
Inhibition of gap junctions sensitizes primary glioblastoma cells for temozolomide
Survivin gene silencing sensitizes prostate cancer cells to selenium growth inhibition
GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment
Targeting TPC2 sensitizes acute lymphoblastic leukemia cells to chemotherapeutics by impairing lysosomal function
Epigenetic preconditioning with decitabine sensitizes glioblastoma to temozolomide via induction of MLH1
BET inhibitor I-BET151 sensitizes GBM cells to temozolomide via PUMA induction
Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF)
BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression
miR-494 Sensitizes Gastric Cancer Cells to TRAIL Treatment Through Downregulation of Survivin
miR-1297 sensitizes glioma cells to temozolomide (TMZ) treatment through targeting adrenomedullin (ADM)